Natixis Advisors L.P. Acquires 19,124 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Natixis Advisors L.P. boosted its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 43.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,962 shares of the biopharmaceutical company's stock after purchasing an additional 19,124 shares during the quarter. Natixis Advisors L.P. owned approximately 0.06% of Cytokinetics worth $5,256,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Mutual of America Capital Management LLC increased its holdings in shares of Cytokinetics by 2.0% during the 4th quarter. Mutual of America Capital Management LLC now owns 17,162 shares of the biopharmaceutical company's stock worth $1,433,000 after buying an additional 337 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Cytokinetics by 4.8% during the third quarter. PNC Financial Services Group Inc. now owns 7,373 shares of the biopharmaceutical company's stock worth $217,000 after acquiring an additional 340 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Cytokinetics by 0.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,684 shares of the biopharmaceutical company's stock worth $1,523,000 after purchasing an additional 359 shares during the period. Arizona State Retirement System lifted its stake in shares of Cytokinetics by 1.4% in the 3rd quarter. Arizona State Retirement System now owns 25,870 shares of the biopharmaceutical company's stock valued at $762,000 after purchasing an additional 363 shares in the last quarter. Finally, HighTower Advisors LLC grew its holdings in shares of Cytokinetics by 5.1% during the 3rd quarter. HighTower Advisors LLC now owns 8,868 shares of the biopharmaceutical company's stock worth $261,000 after purchasing an additional 434 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CYTK. Truist Financial restated a "buy" rating and issued a $86.00 price target on shares of Cytokinetics in a report on Monday, April 8th. UBS Group lowered shares of Cytokinetics from a "buy" rating to a "neutral" rating and lifted their target price for the company from $61.00 to $92.00 in a report on Wednesday, January 24th. Oppenheimer lowered their price target on Cytokinetics from $107.00 to $106.00 and set an "outperform" rating for the company in a report on Thursday. Needham & Company LLC restated a "buy" rating and set a $108.00 price objective on shares of Cytokinetics in a research note on Thursday. Finally, HC Wainwright reiterated a "buy" rating and issued a $94.00 price target on shares of Cytokinetics in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $81.60.

Cytokinetics Price Performance

Shares of CYTK traded down $1.92 during trading hours on Friday, reaching $62.10. 1,343,714 shares of the company's stock traded hands, compared to its average volume of 1,194,795. Cytokinetics, Incorporated has a twelve month low of $25.98 and a twelve month high of $110.25. The business's fifty day simple moving average is $67.42 and its two-hundred day simple moving average is $62.10. The firm has a market capitalization of $6.40 billion, a price-to-earnings ratio of -11.50 and a beta of 0.72.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.17). The business had revenue of $0.84 million for the quarter, compared to the consensus estimate of $0.91 million. The company's quarterly revenue was down 81.8% compared to the same quarter last year. During the same quarter last year, the business earned ($1.38) EPS. On average, equities research analysts expect that Cytokinetics, Incorporated will post -4.5 EPS for the current year.

Insider Buying and Selling

In other Cytokinetics news, Director John T. Henderson sold 5,000 shares of the stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $76.48, for a total transaction of $382,400.00. Following the completion of the transaction, the director now directly owns 42,632 shares of the company's stock, valued at approximately $3,260,495.36. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director John T. Henderson sold 5,000 shares of the firm's stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $76.48, for a total transaction of $382,400.00. Following the completion of the transaction, the director now owns 42,632 shares in the company, valued at approximately $3,260,495.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director John T. Henderson sold 10,562 shares of Cytokinetics stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $64.54, for a total transaction of $681,671.48. Following the completion of the transaction, the director now directly owns 32,070 shares in the company, valued at approximately $2,069,797.80. The disclosure for this sale can be found here. Insiders have sold a total of 96,318 shares of company stock valued at $6,701,940 over the last quarter. Corporate insiders own 3.40% of the company's stock.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.